{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:16Z","timestamp":1793155816405,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Hengrui Pharmaceutical Co. Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical success of IL-17\/IL-23 pathway biologics for the treatment of moderate to severe psoriasis suggests that targeting ROR\u03b3t, a master regulator for the proliferation and function of Th17 cells, could be an effective alternative. However, oral ROR\u03b3 antagonists (VTP43742, TAK828) with\u00a0high systemic exposure showed toxicity in phase I\/II clinical trials and terminated development. To alleviate the potential safety concerns, identifying compounds with skin-restricted exposure amenable for topical use is of great interest. Systematic structure activity relationship study and multi-parameter optimization led to the discovery of a novel ROR\u03b3 antagonist (SHR168442) with desired properties for a topical drug. It suppressed the transcription of IL-17 gene, leading to reduction of IL-17 cytokine secretion. It showed high exposure in skin, but low in plasma. Topical application of SHR168442\u00a0in Vaseline exhibited excellent efficacy in the imiquimod-induced and IL-23-induced psoriasis-like skin inflammation mouse models and correlated with the reduction of Th17 pathway cytokines, IL-6, TNF\u03b1 and IL-17A. This work demonstrated restricted skin exposure of ROR\u03b3 antagonist may provide a new topical treatment option as targeted therapeutics for mild to moderate psoriasis patients and may be suitable for the treatment of any other inflammatory disorders that are accessible locally.<\/jats:p>","DOI":"10.1038\/s41598-021-88492-1","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T10:04:55Z","timestamp":1619604295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Discovery of a novel ROR\u03b3 antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis"],"prefix":"10.1038","volume":"11","author":[{"given":"Suxing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinfa","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"88492_CR1","unstructured":"World Health Organization. Global Report on Psoriasis, 2016; Available from: https:\/\/www.who.int\/publications\/i\/item\/global-report-on-psoriasis (last accessed October 27, 2020)"},{"key":"88492_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jdv.15277","volume":"33","author":"LM Sawyer","year":"2019","unstructured":"Sawyer, L. M. et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J. Eur. Acad. Dermatol. Venereol. 33, 355\u2013366 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"88492_CR3","doi-asserted-by":"publisher","first-page":"e0220868","DOI":"10.1371\/journal.pone.0220868","volume":"14","author":"LM Sawyer","year":"2019","unstructured":"Sawyer, L. M. et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE 14, e0220868 (2019).","journal-title":"PLoS ONE"},{"key":"88492_CR4","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jid.2017.07.065","volume":"137","author":"AG Ellis","year":"2017","unstructured":"Ellis, A. G., Flohr, C. & Drucker, A. M. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: original articles: Jabbar-Lopez, Z. K., et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J. Invest. Dermatol. 137, 1646\u20131654 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"88492_CR5","first-page":"CD011535","volume":"12","author":"E Sbidian","year":"2017","unstructured":"Sbidian, E. et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst. Rev. 12, CD011535 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"88492_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjd.16809","volume":"180","author":"E Sbidian","year":"2019","unstructured":"Sbidian, E. et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Br. J. Dermatol. 180, 282\u2013288 (2019).","journal-title":"Br. J. Dermatol."},{"key":"88492_CR7","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata, M. & Tada, Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int. J. Mol. Sci. 21, 1690 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"88492_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes, M. A., Su\u00e1rez-Fari\u00f1as, M. & Krueger, J. G. Immunology of psoriasis. Annu. Rev. Immunol. 32, 227\u2013255 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"88492_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"BS Ivanov-McKenzie II","year":"2006","unstructured":"Ivanov-McKenzie, B. S. II. et al. The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121\u20131133 (2006).","journal-title":"Cell"},{"key":"88492_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543776.2017.1262350","volume":"27","author":"C Gege","year":"2017","unstructured":"Gege, C. ROR\u03b3t inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345. Expert Opin. Ther. Pat. 27, 1\u20138 (2017).","journal-title":"Expert Opin. Ther. Pat."},{"key":"88492_CR11","unstructured":"Takeda FY2016 Q4 Results, May 2017."},{"key":"88492_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1021\/acsmedchemlett.5b00122","volume":"6","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. Discovery of biaryl amides as potent, orally bioavailable, and CNS penetrant ROR\u03b3t inhibitors. ACS Med. Chem. Lett. 6, 787\u2013792 (2015).","journal-title":"ACS Med. Chem. Lett."},{"key":"88492_CR13","doi-asserted-by":"publisher","first-page":"e003","DOI":"10.1621\/nrs.07003","volume":"7","author":"AM Jetten","year":"2009","unstructured":"Jetten, A. M. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl. Recept. Signal 7, e003 (2009).","journal-title":"Nucl. Recept. Signal"},{"key":"88492_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04261.x","volume":"163","author":"JD Campbell","year":"2011","unstructured":"Campbell, J. D. et al. Rapid detection, enrichment and propagation of specific T cell subsets based on cytokine secretion. Clin. Exp. Immunol. 163, 1\u201310 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"88492_CR15","first-page":"22702","volume":"286","author":"T Xu","year":"2011","unstructured":"Xu, T. et al. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of ROR gamma protein. J. Biol. Chem. 286, 22702\u201322710 (2011).","journal-title":"J. Biol. Chem."},{"key":"88492_CR16","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1016\/j.bmcl.2014.09.053","volume":"24","author":"C Gege","year":"2014","unstructured":"Gege, C., Schluter, T. & Hoffmann, T. Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for ROR\u03b2 and ROR\u03b3t. Bioorganic Med. Chem. Lett. 24, 5265\u20135267 (2014).","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"88492_CR17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nrd3845","volume":"11","author":"J Bowes","year":"2012","unstructured":"Bowes, J. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909\u2013922 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"88492_CR18","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"L van der Fits","year":"2009","unstructured":"van der Fits, L. et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J. Immunol. 182, 5836\u20135845 (2009).","journal-title":"J. Immunol."},{"key":"88492_CR19","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.4049\/jimmunol.1001001","volume":"186","author":"HL Rizzo","year":"2011","unstructured":"Rizzo, H. L. et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J. Immunol. 186, 1495\u20131502 (2011).","journal-title":"J. Immunol."},{"key":"88492_CR20","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.4049\/jimmunol.0900368","volume":"183","author":"HR Yen","year":"2009","unstructured":"Yen, H. R. et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J. Immunol. 183, 7161\u20137168 (2009).","journal-title":"J. Immunol."},{"key":"88492_CR21","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1002\/eji.201242569","volume":"42","author":"CE Sutton","year":"2012","unstructured":"Sutton, C. E., Mielke, L. A. & Mills, K. H. IL-17-producing \u03b3\u03b4 T cells and innate lymphoid cells. Eur. J Immunol. 42, 2221\u20132231 (2012).","journal-title":"Eur. J Immunol."},{"key":"88492_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1146\/annurev-immunol-020711-075053","volume":"30","author":"H Spits","year":"2012","unstructured":"Spits, H. & Cupedo, T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 30, 647\u2013675 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"88492_CR23","doi-asserted-by":"publisher","first-page":"17003","DOI":"10.1074\/jbc.M801286200","volume":"283","author":"K Ichiyama","year":"2008","unstructured":"Ichiyama, K. et al. Foxp3 inhibits RORgamma t-mediated IL-17A mRNA transcription through direct interaction with RORgamma t. J. Biol. Chem. 283, 17003\u201317008 (2008).","journal-title":"J. Biol. Chem."},{"key":"88492_CR24","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1084\/jem.20110462","volume":"208","author":"Q Ruan","year":"2011","unstructured":"Ruan, Q. et al. The Th17 immune response is controlled by the Rel-ROR\u03b3-ROR\u03b3 T transcriptional axis. J. Exp. Med. 208, 2321\u20132333 (2011).","journal-title":"J. Exp. Med."},{"key":"88492_CR25","first-page":"901","volume":"62","author":"E Ueda","year":"2002","unstructured":"Ueda, E. et al. High incidence of T-cell lymphomas in mice deficient in the retinoid-related orphan receptor RORgamma. Cancer Res. 62, 901\u2013909 (2002).","journal-title":"Cancer Res."},{"key":"88492_CR26","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.autrev.2016.07.036","volume":"15","author":"M Liljevald","year":"2016","unstructured":"Liljevald, M. et al. Retinoid-related orphan receptor \u03b3 (ROR\u03b3) adult induced knockout mice develop lymphoblastic lymphoma. Autoimmun. Rev. 15, 1062\u20131070 (2016).","journal-title":"Autoimmun. Rev."},{"key":"88492_CR27","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/bjd.16131","volume":"178","author":"EG Kang","year":"2018","unstructured":"Kang, E. G. et al. A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test. Br. J. Dermatol. 178, 1427\u20131429 (2018).","journal-title":"Br. J. Dermatol."},{"key":"88492_CR28","doi-asserted-by":"publisher","first-page":"e0147979","DOI":"10.1371\/journal.pone.0147979","volume":"11","author":"SH Smith","year":"2016","unstructured":"Smith, S. H. et al. Development of a topical treatment for psoriasis targeting ROR\u03b3: from bench to skin. PLoS ONE 11, e0147979 (2016).","journal-title":"PLoS ONE"},{"key":"88492_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1590\/S1984-82502013000300004","volume":"49","author":"A Nair","year":"2013","unstructured":"Nair, A., Jacob, S., Al-Dhubiab, B., Attimarad, M. & Harsha, S. Basic considerations in the dermatokinetics of topical formulations. Braz. J. Pharm Sci. 49, 423\u2013434 (2013).","journal-title":"Braz. J. Pharm Sci."},{"key":"88492_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/15569527.2016.1178277","volume":"36","author":"A Stricker-Krongrad","year":"2017","unstructured":"Stricker-Krongrad, A., Shoemake, C. R., Liu, J., Brocksmith, D. & Bouchard, G. The importance of minipigs in dermal safety assessment: an overview. Cutan. Ocul. Toxicol. 36, 105\u2013113 (2017).","journal-title":"Cutan. Ocul. Toxicol."},{"key":"88492_CR31","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jps.24383","volume":"104","author":"A Mitra","year":"2015","unstructured":"Mitra, A. et al. Use of minipig skin biopsy model as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans. J. Pharm Sci. 104, 1701\u20131708 (2015).","journal-title":"J. Pharm Sci."},{"key":"88492_CR32","first-page":"280","volume":"137","author":"G Krueger","year":"2001","unstructured":"Krueger, G. et al. The impact of psoriasis on quality of life: results of a 1998 national psoriasis foundation patient\u2014membership survey. Arch. Dermatol. 137, 280\u2013284 (2001).","journal-title":"Arch. Dermatol."},{"key":"88492_CR33","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3904\/kjim.2017.207","volume":"33","author":"L Liang","year":"2018","unstructured":"Liang, L. et al. Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model. Korean J. Intern. Med. 33, 1210\u20131223 (2018).","journal-title":"Korean J. Intern. Med."},{"key":"88492_CR34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4049\/jimmunol.1602144","volume":"199","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. IFN-\u03b3-expressing Th17 cells are required for development of severe ocular surface autoimmunity. J. Immunol. 199, 1163\u20131169 (2017).","journal-title":"J. Immunol."},{"key":"88492_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/prot.22234","volume":"75","author":"P Labute","year":"2009","unstructured":"Labute, P. Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins 75, 187\u2013205 (2009).","journal-title":"Proteins"},{"key":"88492_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1021\/ml4003875","volume":"5","author":"T Yang","year":"2013","unstructured":"Yang, T. et al. Discovery of Tertiary Amine and Indole Derivatives as Potent ROR\u03b3t Inverse Agonists. ACS Med. Chem. Lett. 5, 65\u201368 (2013).","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88492-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88492-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88492-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:20:54Z","timestamp":1670052054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88492-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88492"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88492-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L., R.S., D.L.<sup>1<\/sup>, D.L.<sup>2<\/sup>, Y.Y., F.Z., R.Z., J.L. were employees of Eternity Bioscience Inc. and J.S., Q.H., H.W., P.D., J.F., L.Z., W.T. were employees and shareholders of Hengrui Pharmaceutical Co. Ltd. D.L.<sup>1<\/sup> = Dong Liu; D.L.<sup>2<\/sup> = Di Li.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9132"}}